InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally

NEW YORK, NY / ACCESS Newswire / November 21, 2025 / InnerMost PBC, New York City's new psychedelic-assisted therapy center dedicated to accessible care, practitioner training, FDA-authorized clinical trials, and community building, is officially open.

A public benefit corporation, InnerMost provides accessible ketamine and Spravato therapy, is an FDA-trial site that trains psychedelic-assisted therapists, and builds community amongst clinicians in this paradigm-shifting field.

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing access and progress globally. New hope emerges as the mainstream embraces new evidence-based approaches that expand what's possible in mental health care.

Leading conversations about psychedelic therapy's past, present and future is Casey Paleos, MD, (CV) Co-Founder & Chief Medical Officer, board-certified psychiatrist and researcher with 15+ years in psychedelic-assisted therapy. As figures like Rick Doblin pass the baton, they sing praises about his body of work and vision:

  • Principal Investigator, MAPS MDMA therapy for PTSD Studies

  • Therapist, NYU Psilocybin Cancer Anxiety Study

  • Co-Founder, Nautilus Sanctuary

  • Founding Board Member, International Alliance of MDMA Practitioners

  • Presenter, "Understanding Ketamine" Workshop, Psychotherapy Networker conference, Washington, D.C.

  • Co-Author of "Inner-Directed Therapy in MDMA-Assisted Psychotherapy," newly released commentary on the MDMA debate in the American Journal of Psychiatry

WHY INNERMOST IS DIFFERENT:

  • Research:FDA-authorized clinical trial site, including ongoing MDMA research and more TBA.

  • Treatment: Integration of psychotherapy with ketamine, Spravato, and future integrative mental health modalities.

  • Training: Practicum training, mentorship and clinical supervision.

  • Education & Community: Public programming, podcasts, panels, and partnerships.

  • Accessibility: Public benefit corporation whose mission is to eliminate socioeconomic barriers to accessing psychedelic therapies.

VISUALS:

  • First look at InnerMost's space and design.

  • Interviews with Dr. Paleos and team.

  • Photo and video opportunities.

Now open to the public by appointment at innermost.one, media are invited to schedule private tours of InnerMost.

MEDIA CONTACT: Marissa Feinberg | marissa@triplebottomwhy.com | 917-494-5041

SOURCE: InnerMost



View the original press release on ACCESS Newswire

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.88
+0.66 (0.28%)
AAPL  283.10
+4.25 (1.52%)
AMD  219.76
+2.23 (1.03%)
BAC  53.24
-0.41 (-0.76%)
GOOG  315.12
-5.00 (-1.56%)
META  640.87
-7.08 (-1.09%)
MSFT  486.74
-5.27 (-1.07%)
NVDA  179.92
+2.92 (1.65%)
ORCL  200.94
-1.01 (-0.50%)
TSLA  430.14
-0.03 (-0.01%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.